A neuropharmaceutical research entity built on original science and a commitment to kinetic precision.
The next generation of neurological treatment should be defined by precision of regulation, not absolute neurotransmitter volume.
ÆVIANT BIOSCIENCES exists to develop therapeutics that restore the brain's endogenous processing capacity. The program direction centers on kinetic control of signal termination and clinically practical state-management use models.
Immanuel Martins is a neuropharmacology researcher and the sole architect of the ÆVIANT therapeutic framework.
The kinetic precision hypothesis, lead candidate strategy, intranasal deployment framework, retrometabolic safety architecture, and biomarker stratification system originate from independent research.
ÆVIANT was founded to translate this framework from theory into a regulated therapeutic program.
Kinetic Precision Framework
Translation Path
All mechanisms, molecular specifications, delivery protocols, and therapeutic frameworks described by ÆVIANT BIOSCIENCES are the proprietary intellectual property of Immanuel Martins. Patent applications covering composition-of-matter and method-of-use claims are filed and under review. Unauthorised reproduction, distribution, or disclosure of proprietary information is strictly prohibited.
For research inquiries, regulatory correspondence, or partnership discussions.